The New England journal of medicineAdultAged80 and overFemaleHumans
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.
Xinan Sheng, Gongqian Zeng, Cuijian Zhang, Qingyun Zhang, Jiasheng Bian, Haitao Niu, Jun Li, Yanxia Shi, Kai Yao, Bin Hu, Ziling Liu, Hong Liao, Zhixian Yu, Baiye Jin, Peng Zhao
Published: 202510.1056/NEJMoa2511648
Abstract
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate monotherapy has shown preliminary clinical efficacy in patients with chemotherapy-refractory HER2-positive locally advanced or metastatic urothelial cancer.…
Preview only. Read the full abstract at the source